Assessing the impact of cholera vaccination in endemic areas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project evaluates the effectiveness of oral cholera vaccine mass campaigns in urban and rural areas of the Democratic Republic of the Congo (DRC). It includes clinical cholera surveillance to measure disease incidence, serological surveys to assess recent infection prevalence, and follow-up of individuals shedding V. cholerae. The goal is to determine if high vaccination coverage can sustain cholera control for at least two years. The findings will inform future cholera vaccination strategies in high-burden regions.

Why it matters

Who can join: the full rules

For Surveillance in study CTCs

Inclusion Criteria:

* All patients presenting at the time of the study to any selected Cholera Treatment Center/Cholera Treatment Unit (CTC/CTU), matching the case definition and giving his/her consent (or assent for children 8 to 17 years old) to participate in the study will be eligible.

Exclusion Criteria:

* Patients who decline to participate will be excluded from the study.

Follow up of individuals with active cholera shedding:

Inclusion Criteria:

1. present to any selected CTC/CTU, match the case definition, participate to the clinical surveillance activity and test positive to RDT OR
2. Be a household member of a person respecting inclusion criteria 1. AND for whom the head of the household has provided verbal consent to participate AND giving his/her consent (or assent for children 8 to 17 years old) to participate in the study will be eligible.

Exclusion Criteria:

\- Individuals who decline to participate will be excluded from the study, as well as households for whom the head of the household (and his or her representative) decline the participation of his/her household.

Where it's running

• Anais Broban
  Goma, Democratic Republic of the Congo Recruiting

Study contacts

• Study coordinator: Anais BROBAN
• Email: anais.broban@epicentre.msf.org
• Phone: +33140215494

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cholera control around a case area using targeted vaccination (CATI) in Dhaka

  This study tests whether vaccinating household contacts around a cholera case in Dhaka can reduce transmission of the disease.

  Recruiting International Centre for Diarrhoeal Disease Research, Bangladesh · Dhaka · NCT07685574

• Testing a new approach to reduce cholera and diarrhea in households

  This study is testing a new program to see if better water and hygiene practices can help reduce cholera and diarrhea in homes with young children.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Mānikganj · NCT06498817

• Identifying immune markers for cholera vaccine effectiveness

  This study is testing if certain immune markers can show how well the cholera vaccine works in people receiving it compared to those getting a different vaccine.

  Recruiting Massachusetts General Hospital · Dhaka · NCT06455852

• Targeted water, sanitation, and hygiene intervention for cholera prevention

  This study is testing a new water, sanitation, and hygiene program to see if it can help people living near cholera patients stay healthy and reduce infections.

  Recruiting at 2 sites Johns Hopkins Bloomberg School of Public Health · Dhaka and 1 other locations · NCT06003816

• Preventing cholera through targeted water and hygiene interventions

  This study is testing a new way to improve water and hygiene practices for families of diarrhea patients in the Democratic Republic of the Congo to see if it can help prevent cholera.

  Recruiting at 2 sites Johns Hopkins Bloomberg School of Public Health · Bukavu, South Kivu and 1 other locations · NCT05166850

• Age-descending safety and immune response of a cholera conjugate vaccine in people aged 1–45

  This trial will test whether one or two doses of a 25 μg cholera conjugate vaccine, with or without an aluminum adjuvant, are safe and produce immune responses in people aged 1 to 45 living in a cholera-endemic area.

  Recruiting Phase 2 International Vaccine Institute · Nairobi, Kenyatta National Hospital Complex · NCT07509047

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.